Amylyx Pharmaceuticals, Inc.

AMLX Healthcare Drug Manufacturers Specialty & Generic

Amylyx Pharmaceuticals, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $87.4 million, down 77.1% from fiscal 2023. In the quarter to June 2026, revenue fell 100.6%, EPS grew 15.2% and free cash flow fell 24.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

26.34 1.31 −4.74%
Market cap
$3.5B
P/E
0.0×
Fwd P/E
−9.2×
Dividend yield
—
F-score
3/9
Altman Z
−2.95
Beneish M
n/a
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
13.70 14.27 17.85 12.12
Net Debt/EBITDA
9.26 8.44 6.32 5.35
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.33) (0.30) (0.37) (0.28)
Book value per Share
3.56 3.23 2.47 2.15
Free Cash Flow
(30.39) (27.99) (40.88) (31.45)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates